Inactive Instrument

Aralez Pharmaceuticals Inc Stock Nasdaq

Equities

CA03852X1006

Pharmaceuticals

Sales 2016 54.27M Sales 2017 106M Capitalization 94.98M
Net income 2016 -103M Net income 2017 -125M EV / Sales 2016 9.18 x
Net Debt 2016 209M Net Debt 2017 246M EV / Sales 2017 3.22 x
P/E ratio 2016
-2.53 x
P/E ratio 2017
-0.75 x
Employees -
Yield 2016 *
-
Yield 2017
-
Free-Float 100%
More Fundamentals * Assessed data
Dynamic Chart
Old API Wind-Down Ltd. Announces Management Changes CI
Aralez Pharmaceuticals Inc. has Changed its Name to Old API Wind-down Ltd CI
Aralez Pharmaceuticals Inc. Announces Management Changes CI
Nuvo Pharmaceuticals Inc. completed the acquisition of Aralez Pharmaceuticals Canada Inc. from Aralez Pharmaceuticals Inc.. CI
Aralez Pharmaceuticals Inc.(NasdaqGS:ARLZ) dropped from NASDAQ Composite Index CI
Aralez Pharmaceuticals Inc. Announces the Resignation of Seth A. Rudnick, Neal F. Fowler and Rob Harris as Directors CI
Nuvo Pharmaceuticals Inc. signed a letter of intent to acquire Aralez Pharmaceuticals Canada Inc. from Aralez Pharmaceuticals Inc. for $62.5 million. CI
Aralez Pharmaceuticals Inc. Announces Resignation of James Tursi as Chief Medical Officer, Effective from August 2, 2018 CI
Aralez Pharmaceuticals Inc. Enters into an Amendment to that Certain Second Amended and Restated Facility Agreement with Deerfield Partners, L.P CI
Transcript : Aralez Pharmaceuticals Inc., Q1 2018 Earnings Call, May 08, 2018
Aralez Pharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2018 CI
Aralez Pharmaceuticals Inc. Announces Resignation of Mark Glickman as Chief Commercial Officer, Effective on March 30, 2018 CI
Aralez Pharmaceuticals Inc. Appoints Michael Kaseta as Chief Financial Officer CI
Transcript : Aralez Pharmaceuticals Inc., Q4 2017 Earnings Call, Mar 13, 2018
Aralez Pharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2017; Provides Earnings Guidance for the Fiscal Year 2018 CI
More news
Old API Wind-Down Ltd, formerly Aralez Pharmaceuticals Inc., is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company's products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G. Its development products include YOSPRALA and Bilastine. Fibricor (fenofibric acid) is indicated as a complementary therapy along with diet for the treatment of hypertriglyceridemia, and as a complementary therapy along with diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG) and apolipoprotein B (Apo B). Fibricor is also used to increase high-density lipoprotein (HDL) cholesterol (HDL-C) in patients with hypercholesterolemia or mixed dyslipidemia. Cambia (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug (NSAID).
More about the company